Measuring the Prevalence of Chronic Kidney Disease among Type 2 Diabetes Mellitus Patient in Hospital Jitra: A Population-Based Cohort Study
Article Sidebar
Main Article Content
Abstract
Introduction: Chronic kidney disease (CKD) develops in approximately 40% of patients with diabetes. The prevalence of CKD in Malaysia is 9.07% among adults. It is important to obtain accurate local data on CKD among patient with Type 2 Diabetes Mellitus (T2DM) patients to facilitate health-care planning including the review of health-care priorities, program activities, and allocation of resources. The objective of this study is to determine the prevalence of CKD among DM. We further explored the association between glycaemic control, eGFR and adverse outcomes (cardiovascular events, hospitalizations, and kidney failure) among these patients. Materials and method: This is a retrospective cohort study involving 91 DM patients who received treatment in Hospital Jitra, Kedah, Malaysia. Patients’ demographic data, comorbidities, history of hospital admission, medications, complication, and laboratory test results were retrieved from their medical record. Descriptive and inferential statistics have been used to analyse the data. Results: 60.4% of the patients were female and 85.7% Malay with mean age of 62.15 years old. Hypertension, hypercholesterolemia and heart disease were the most common comorbidities among them; 92.3%, 78.0%, and 23.1%, respectively. The prevalence of CKD among DM in Hospital Jitra was 38.46%. 20.9% of the patients experienced diabetic complications and 49.5% showed a progression of kidney disease. The results indicate a high percentage of poor glycaemic control among DM in Hospital Jitra; 69%-100% of the patients had HbA1c >7% at each visit and this is associated with CKD (P=0.042). Conclusion: The prevalence of CKD among DM patients at Hospital Jitra was 38.46%. Higher HbA1c was associated with CKD in adults with type DM, suggesting that improving glycaemic control may reduce the risk of CKD.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal of Pharmacy at https://journals.iium.edu.my/ktn/index.php/jp is licensed under a Creative Commons Attribution 4.0 International License.
References
The ACCORD Study Group. (2011). Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine, 364(9), 818–828. https://doi:10.1016/S0084-3741(09)79280-7 DOI: https://doi.org/10.1056/NEJMoa1006524
Advani A. (2020). Positioning time in range in diabetes management. Diabetologia, 63(2), 242–252. https://doi.org/10.1007/s00125-019-05027-0 DOI: https://doi.org/10.1007/s00125-019-05027-0
American Diabetes Association. (2021). Diabetic kidney disease (DKD). Diabetes Care, 44(Supplement 1), S163–S184. https://doi.org/10.2337/dci21-0014 DOI: https://doi.org/10.2337/dci21-0014
American Diabetes Association. (2023). Diabetes and Kidney Disease. Diabetes Care, 46(Supplement 1), S171–S180. https://doi.org/10.2337/dci22-0034 DOI: https://doi.org/10.2337/dci22-0034
American Diabetes Association. (2023). Cardiovascular Disease and Risk Management. Diabetes Care, 46(Supplement 1), S158-S168. https://doi.org/10.2337/dci22-0067 DOI: https://doi.org/10.2337/dci22-0067
American Diabetes Association. (2023). Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes—2023. Diabetes Care, 46(Supplement 1), S111-S124. https://doi.org/10.2337/dc23-S011 DOI: https://doi.org/10.2337/dc23-S011
Buse, J. B., Wexler, D. J., et al. (2020). Treatment of type 2 diabetes with GLP-1 receptor agonists and insulin. Diabetes Care, 43(2), 241-250. https://doi.org/10.2337/dci19-0065 DOI: https://doi.org/10.2337/dci19-0065
Centers for Disease Control and Prevention. (2021). Chronic Kidney Disease in the United States, 2021. U.S. Department of Health and Human Services. Available at: https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html
Chalmers, J., et al. (2010). The effects of intensive glucose lowering on kidney disease progression in patients with type 2 diabetes. Journal of the American Society of Nephrology, 21(3), 507–514. https://doi.org/10.1681/ASN.2009090974
Dhand, N. K., & Khatkar, M. S. (2014). Statulator: an online statistical calculator. Sample size calculator for estimating a single proportion. [Internet]. Accessed 27 November 2022 at http://statulator.com/SampleSize/ss1P.html
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018). Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovascular diabetology, 17, 1-19. https://doi.org/10.1186/s12933-018-0728-6 DOI: https://doi.org/10.1186/s12933-018-0728-6
Garla, V., Yanes-Cardozo, L., & Lien, L. F. (2017). Current therapeutic approaches in the management of hyperglycemia in chronic renal disease. Reviews in Endocrine and Metabolic Disorders, 18(1), 5–19. https://doi.org/10.1007/s11154-017-9416-1 DOI: https://doi.org/10.1007/s11154-017-9416-1
Gross, J. L., De Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., & Zelmanovitz, T. (2005). Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes care, 28(1), 164-176. https://doi.org/10.2337/diacare.28.1.164 DOI: https://doi.org/10.2337/diacare.28.1.164
Harrington, J. E., & Ward, C. (2019). Challenges in managing diabetes in patients with chronic kidney disease. American Journal of Kidney Diseases, 74(4), 442-448. https://doi.org/10.1053/j.ajkd.2019.02.341
Jitraknatee, J., Ruengorn, C., & Nochaiwong, S. (2020). Prevalence and risk factors of chronic kidney disease among type 2 diabetes patients: a cross-sectional study in primary care practice. Scientific reports, 10(1), 6205. https://doi.org/10.1038/s41598-020-63443-4 DOI: https://doi.org/10.1038/s41598-020-63443-4
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. (2020). KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International, 98(4), S1-S115. https://doi.org/10.1016/j.kint.2020.05.032 DOI: https://doi.org/10.1016/j.kint.2020.06.019
Khan, N., Huxley, R. R., & Bakris, G. L. (2020). The global burden of chronic kidney disease and diabetes: Implications for the economic and healthcare system. Clinical Journal of the American Society of Nephrology, 15(5), 654-661. https://doi.org/10.2215/CJN.04550420
Kong, A. P., Yang, X., Luk, A., Ma, R. C., So, W. Y., Ozaki, R., ... & Chan, J. C. (2014). Severe hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: the Hong Kong diabetes registry. Diabetes Care, 37(4), 1024-1031. https://doi.org/10.2337/dc13-2507 DOI: https://doi.org/10.2337/dc13-2507
Kurzhagen, J. T., Dellepiane, S., Cantaluppi, V., & Rabb, H. (2020). AKI: an increasingly recognized risk factor for CKD development and progression. Journal of Nephrology, 33(6), 1171-1187. https://doi.org/10.1007/s40620-020-00793-2 DOI: https://doi.org/10.1007/s40620-020-00793-2
Lazarus, B., & Wu, A. W. (2020). Barriers to the use of newer therapies in diabetes management. Journal of Clinical Endocrinology & Metabolism, 105(4), 1367-1375. https://doi.org/10.1210/clinem/dgz227 DOI: https://doi.org/10.1210/clinem/dgz227
Mann, J. F. E., Fonseca, V., Mosenzon, O., Raz, I., Goldman, B., Idorn, T., Von Scholten, B. J., & Poulter, N. R. (2018). Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease: Results from the LEADER trial. Circulation, 138(25), 2908–2918. https://doi.org/10.1161/CIRCULATIONAHA.118.036418 DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.036418
McMurray, J. J. V., Solomon, S. D., et al. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995-2008. https://doi.org/10.1056/NEJMoa1911303 DOI: https://doi.org/10.1056/NEJMoa1911303
Malaysian Health Technology Assessment Section (MaHTAS), Ministry of Health Malaysia. Clinical Practice Guidelines on the Management of Chronic Kidney Disease (2nd ed. 2018). https://www.moh.gov.my/moh/resources/penerbitan/CPG/CPG%20Management%20of%20Chronic%20Kidney%20%20Disease%20(Second%20Edition).pdf
Mohd Zuki, A. H., & Isa, M. R. (2022). Chronic Kidney Disease Staging Among Type II Diabetes Mellitus Patients in Kedah, Malaysia: Prevalence and its Factor Associated. J Pub Health Issue Pract, 6(1), 198. J Pub Health Issue Pract, 6(1): 198 https://doi.org/10.33790/jphip1100198 DOI: https://doi.org/10.33790/jphip1100198
National Kidney Foundation. (2022). Diabetic Kidney Disease: A Global Epidemic. Retrieved from https://www.kidney.org/atoz/content/diabetic-kidney-disease
Nitta, K., Okada, K., Yanai, M., & Takahashi, S. (2014). Aging and chronic kidney disease. Kidney and Blood Pressure Research, 38(1), 109-120. https://doi.org/10.1159/000355760 DOI: https://doi.org/10.1159/000355760
Pisters, R., van der Auwera, J., & Peters, W. (2017). Diabetic Kidney Disease and Cardiovascular Risk: A Systematic Review. Clinical Kidney Journal, 10(5), 685-691. https://doi.org/10.1093/ckj/sfx049 DOI: https://doi.org/10.1093/ckj/sfx049
Real Time World Statistics. Malaysia population [Internet]; 2024 [Retrieved 2024 April 23]. Available at: https://www.worldometers.info/ world-population/malaysia-population/
Sinha, N., & Bansal, S. (2019). Pharmacokinetics and pharmacodynamics of anti-hyperglycemic drugs in patients with chronic kidney disease. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 13(2), 1135-1144. https://doi.org/10.1016/j.dsx.2019.02.002 DOI: https://doi.org/10.1016/j.dsx.2019.02.002
Saminathan, T. A., Hooi, L. S., Mohd Yusoff, M. F., Ong, L. M., Bavanandan, S., Rodzlan Hasani, W. S., ... & Aris, T. (2020). Prevalence of chronic kidney disease and its associated factors in Malaysia; findings from a nationwide population-based cross-sectional study. BMC nephrology, 21, 1-11. DOI: https://doi.org/10.1186/s12882-020-01966-8
Zhang, Y., Li, X., & Liu, Z. (2021). Management of diabetic kidney disease: A comprehensive approach to optimize renal and cardiovascular outcomes. Journal of Diabetes Research, 2021, 1-12. https://doi.org/10.1155/2021/8994087